Download Advanced Refractory Solid Tumors or Breast

Inspira (Vineland/Woobury) Open Clinical Trials
as of June 18, 2015
Advanced Refractory Solid Tumors or
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
EAY131 (NCI CIRB)
Woodbury: (856) 853-2075
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors or Lymphomas "MATCH"
Why the study is being done/Purpose:
PURPOSE/RATIONALE: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that
have progressed following at least one line of standard treatment or for whom no standard treatment exists. Genetic tests look at the unique genetic material
(genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which
targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors
or lymphomas.
Breast
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ALLIANCE A011106 NCI CIRB
Woodbury: (856) 853-2075
Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women:
A Phase III Study
Why the study is being done/Purpose:
PURPOSE: This randomized phase III trial has several primary objectives. One primary objective is to compare the efficacy of 3 different endocrine therapies, the
estrogen receptor down regulator fulvestrant and the aromatase inhibitor anastrozole, either alone or in combination, in reducing cancer growth before surgery
(neoadjuvant) in postmenopausal women with clinical stage II-III estrogen receptor positive and HER2 negative breast cancer. Another primary objective is to
evaluate whether patients who achieved a modified PEPI (Preoperative Endocrine Prognostic Index) score of 0, defined by tumor size <5 cm, N0, Ki67<2.7% (by
central testing), at surgery post 6 months of neoadjuvant endocrine therapy predict excellent long term outcome, for whom chemotherapy is unnecessary.
PRINTED 6/18/2015
Page 1
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E2108 CIRB
Woodbury: (856) 853-2075
A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients With Metastatic Breast Cancer
Breast
Why the study is being done/Purpose:
RATIONALE: Early surgery may have fewer side effects and improve recovery. Palliative surgery or radiation therapy may help patients with advanced breast
cancer live more comfortably. It is not yet known whether early surgery is more effective than palliative therapy for advanced breast cancer.
PURPOSE: This randomized phase III trial is studying early surgery to see how well it works compared to standard palliative therapy in treating patients with stage
IV breast cancer.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E2112 NCI CIRB
Woodbury: (856) 853-2075
A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast
Cancer
Why the study is being done/Purpose:
Rationale/Purpose: This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating
postmenopausal patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can
cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes.
Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective
with or without entinostat in treating breast cancer.
Breast
PRINTED 6/18/2015
Page 2
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
NRG-BR003 (NCI CIRB)
Woodbury: (856) 853-2075
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin
for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Why the study is being done/Purpose:
PURPOSE/RATIONALE: The purpose of this study the effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery,
compared to the usual chemotherapy drugs given without carboplatin. This study will allow the researchers to know whether giving carboplatin with the usual
chemotherapy is better, the same, or worse than giving the usual chemotherapy. Carboplatin is FDA-approved for the treatment of cancer and is used for the
treatment of breast cancer that has spread, but it has not yet been proven useful in earlier stages of breast cancer.
Breast
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
NSABP B-52 CIRB NRG
Woodbury: (856) 853-2075
A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable
and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without
Estrogen Deprivation
Why the study is being done/Purpose:
RATIONALE:Drugs used in chemotherapy, such as docetaxel, carboplatin, trastuzumab, and pertuzumab, work in different ways to stop the growth of tumor cells,
either by killing the cells or by stopping them from dividing. Giving more than one drug may kill more tumor cells. Estrogen can cause the growth of breast cancer
cells. Hormone therapy using goserelin acetate and aromatase inhibition therapy may fight breast cancer by blocking the use of estrogen by the tumor cells.
Radiation therapy uses high energy x rays to kill tumor cells. Giving combination chemotherapy and radiation therapy with or without hormone therapy may be an
effective treatment for hormone receptor-positive, HER2-positive, operable or locally advanced breast cancer.
Breast
PURPOSE: This randomized phase III trial studies docetaxel, carboplatin, trastuzumab, and pertuzumab with estrogen deprivation to see how they work compared
to docetaxel, carboplatin, trastuzumab, and pertuzumab without estrogen deprivation in treating patients with hormone receptor-positive, human epidermal growth
factor receptor 2 (HER2)-positive, operable or locally advanced breast cancer.
PRINTED 6/18/2015
Page 3
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S1007 NCI CIRB
Woodbury: (856) 853-2075
A Phase III Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone ReceptorPositive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
Why the study is being done/Purpose:
Rationale: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen
by the tumor cells. Aromatase inhibitors, such as anastrozole, letrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body
makes. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
known whether giving tamoxifen citrate, anastrozole, letrozole, or exemestane is more effective with combination chemotherapy in treating patients with breast
cancer.
Breast
Purpose: This phase III clinical trial is studying how well giving tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy works in
treating patients with invasive breast cancer.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S1202 CTSU
Woodbury: (856) 853-2075
A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Women With
Early Stage Breast Cancer
Why the study is being done/Purpose:
PURPOSE/RATIONALE: This randomized phase III trial studies how well duloxetine hydrochloride works compared to a placebo in treating muscle, bone, and joint
pain in patients with early-stage breast cancer receiving hormone therapy. Duloxetine hydrochloride may lessen muscle, bone, and joint pain caused by hormone
therapy. It is not yet known whether duloxetine hydrochloride is more effective than a placebo in treating patients with muscle, bone, and joint pain caused by
hormone therapy.
Breast
PRINTED 6/18/2015
Page 4
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S0820 CTSU
Woodbury: (856) 853-2075
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in
Patients with Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)
Why the study is being done/Purpose:
The investigators hypothesize that the combination of eflornithine and sulindac will be effective in reducing a three-year event rate of adenomas and second
primary colorectal cancers in patients previously treated for Stages 0 through III colon cancer.
GI Colon
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
CALGB 80702 NCI CIRB
Woodbury: (856) 853-2075
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients With Resected Stage III Colon Cancer
GI Colon-Lower
Why the study is being done/Purpose:
RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either
by killing the cells or by stopping them from dividing. Celecoxib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not
yet known whether giving oxaliplatin, leucovorin calcium, and fluorouracil is more effective with or without celecoxib in treating colon cancer.
PURPOSE: This randomized phase III trial is studying giving oxaliplatin, leucovorin calcium, and fluorouracil together to compare how well they work when given
together with or without celecoxib in treating patients with stage III colon cancer previously treated with surgery.
PRINTED 6/18/2015
Page 5
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E7208
Woodbury: (856) 853-2075
A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras
Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Why the study is being done/Purpose:
RATIONALE: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Monoclonal antibodies, such as cetuximab and ramucirumab, can block tumor growth in different ways. Some block the ability of tumor
cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab and ramucirumab may also stop the
growth of colorectal cancer by blocking blood flow to the tumor. It is not yet know whether giving cetuximab and irinotecan hydrochloride together is more effective
with or without ramucirumab in treating colorectal cancer.
PURPOSE: This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab
work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy.
GI Colorectal
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
FCCC 14-803
Woodbury: (856) 853-2075
Feasibility of Dissemination of Targeted Cancer Panel to Community-Based Colorectal Cancer Patients Supported by Genomic E-Consultation
GI Colorectal
Why the study is being done/Purpose:
RATIONALE/PURPOSE: The purpose of this research study is to find out if it is helpful to offer Targeted Cancer Panel testing to patients with colorectal cancer that
has spread. Targeted Cancer Panel is a test that screens for mutations or changes in cancer related genes in a patient’s tumor specimen.
Depending on the results of the test, the sponsor hopes to find a clinical trial available that uses a drug that can go after or target those changes in the patient's
tumor.
PRINTED 6/18/2015
Page 6
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S1406 NCI CIRB
Woodbury: (856) 853-2075
Randomized Phase II Study of Irinotecan and Cetuximab with or Without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer
GI Colorectal
Why the study is being done/Purpose:
RATIONALE/PURPOSE:This randomized phase II trial studies how well irinotecan hydrochloride and cetuximab with or without vemurafenib works in treating
patients with colorectal cancer that has spread to nearby tissue or lymph nodes, that has spread to other places in the body, or cannot be removed by surgery.
Irinotecan hydrochloride and vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such
as cetuximab, may block the ability of tumor cells to grow and spread. It is not yet known whether irinotecan hydrochloride and cetuximab are more effective with or
without vemurafenib in treating colorectal cancer.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S1314 NCI CIRB
Woodbury: (856) 853-2075
A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer
GU - Bladder
Why the study is being done/Purpose:
PURPOSE: The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a
patient's response to chemotherapy before surgery.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S0931 NCI CIRB
Woodbury: (856) 853-2075
EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study
GU - Renal Cell
Why the study is being done/Purpose:
Rationale: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Purpose: This phase III trial is studying everolimus to see how well it works in treating patients with kidney cancer who have undergone surgery.
PRINTED 6/18/2015
Page 7
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
GOG 0263 CIRB NRG
Woodbury: (856) 853-2075
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical
Hysterectomy and Pelvic Lymphadenectomy
Why the study is being done/Purpose:
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation therapy together with chemotherapy is
more effective than radiation therapy alone in treating patients with cervical cancer.
GYN Cervical
PURPOSE: This trial is studying giving radiation therapy together with chemotherapy to see how well it works compared to radiation therapy alone in treating
patients with stage I or stage II cervical cancer who previously underwent surgery.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E2905 CIRB
Woodbury: (856) 853-2075
A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid®) Alone and in
Combination with Epoetin Alfa (Procrit®) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Why the study is being done/Purpose:
RATIONALE: Lenalidomide may stop the growth of myelodysplastic syndrome by blocking blood flow to the cell. Colony stimulating factors, such as epoetin alfa,
may increase the number of immune cells found in bone marrow or peripheral blood. It is not yet known whether lenalidomide is more effective with or without
epoetin alfa in treating patients with myelodysplastic syndrome and anemia.
Hemotology
PURPOSE: This randomized phase III trial is studying lenalidomide to see how well it works with or without epoetin alfa in treating patients with myelodysplastic
syndrome and anemia.
PRINTED 6/18/2015
Page 8
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ALLIANCE A081105 CIRB - ALCHEMIST - EGFR Tx
Woodbury: (856) 853-2075
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR)
Mutant Non-small Cell Lung Cancer (NSCLC)
Why the study is being done/Purpose:
ALCHEMIST STUDY (EGFR Treatment Component)
PURPOSE: This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell
lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth.
Lung, Non-small Cell
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ALLIANCE A151216 CIRB - ALCHEMIST Woodbury: (856) 853-2075
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Lung, Non-small Cell
Why the study is being done/Purpose:
ALCHEMIST STUDY (Screening Component)
PURPOSE: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by
surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E4512 CIRB - ALCHEMIST - ALK Tx
Woodbury: (856) 853-2075
A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring
the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Why the study is being done/Purpose:
ALCHEMIST STUDY (ALK Treatment Component)
PURPOSE: This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung
cancer that has been removed by surgery and has a mutation in a protein called ALK. Mutations, or changes, in ALK can make it very active and important for
tumor cell growth and progression. Tumors with this mutation may respond to treatments that target the mutation, such as crizotinib. Crizotinib may stop the growth
of tumor cells by blocking the ALK protein from working. It is not yet known if crizotinib may be an effective treatment for treating non-small cell lung cancer with an
ALK fusion mutation.
Lung, Non-small Cell
PRINTED 6/18/2015
Page 9
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S1403 NCI CIRB
Woodbury: (856) 853-2075
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients With Advanced, EGFR Mutation Positive Nonsmall Cell Lung Cancer (NSCLC)
Why the study is being done/Purpose:
RATIONALE/PURPOSE: This randomized phase II/III trial studies how well afatinib dimaleate with cetuximab works and compares it with afatinib dimaleate alone
in treating patients with newly diagnosed stage IV or recurrent (has come back), epidermal growth factor receptor (EGFR) mutation positive non-small cell lung
cancer. Afatinib dimaleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cetuximab,
may block tumor growth in different ways by targeting certain cells. It is not yet known whether afatinib dimaleate is more effective when given alone or with
cetuximab in treating patients with non-small cell lung cancer.
Lung, Non-small Cell
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E1412
Woodbury: (856) 853-2075
Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and
Prednisone) in Patients With Newly Diagnosed Diffuse Large B Cell Lymphoma
Why the study is being done/Purpose:
PURPOSE/RATIONALE: This randomized phase II trial studies how well rituximab and combination chemotherapy with or without lenalidomide works in treating
patients with newly diagnosed stage II-IV diffuse large B cell lymphoma. Monoclonal antibodies, such as rituximab, can block cancer growth in different ways.
Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in
chemotherapy, such as cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone, work in different ways to stop the growth of cancer cells,
either by killing the cells or by stopping them from dividing. Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. It
is not yet known whether rituximab and combination chemotherapy are more effective when given with or without lenalidomide in treating patients with diffuse large
B cell lymphoma.
Lymphoma
PRINTED 6/18/2015
Page 10
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E3612
Woodbury: (856) 853-2075
A Randomized Phase II Trial of Ipilimumab With or Without Bevacizumab in Patients With Unresectable Stage III or Stage IV Melanoma
Melanoma
Why the study is being done/Purpose:
PURPOSE/RATIONALE: This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV
melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and bevacizumab, can block tumor growth in different ways. Some block
the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
Alliance CALGB 30901 CTSU
Woodbury: (856) 853-2075
Randomized Phase II Study of Maintenance Pemetrexed Versus Observation for Patients With Malignant Pleural Mesothelioma Without Progression After
First-Line Chemotherapy
Why the study is being done/Purpose:
RATIONALE: Pemetrexed disodium may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Mesothelioma
PURPOSE: This randomized phase II trial is studying how well pemetrexed disodium or observation works in treating patients with malignant pleural mesothelioma
without progressive disease after first-line chemotherapy.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E1A11 (NCI CIRB)
Woodbury: (856) 853-2075
Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by
Limited or Indefinite Lenalidomide Maintenance in Patients With Newly Diagnosed Symptomatic Multiple Myeloma
Why the study is being done/Purpose:
PURPOSE/RATIONALE: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib,
lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by
blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the
growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone
may kill more cancer cells
Myeloma
PRINTED 6/18/2015
Page 11
as of June 18, 2015
Inspira (Vineland/Woodbury) Open Clinical Trials
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
ECOG-ACRIN E3A06 (NCI CIRB)
Woodbury: (856) 853-2075
Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma
Myeloma
Why the study is being done/Purpose:
PURPOSE/RATIONALE: This phase II/III trial studies how well lenalidomide works and compares it to observation in treating patients with asymptomatic high-risk
smoldering multiple myeloma. Biological therapies such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing.
Sometimes the cancer may not need treatment until it progresses. In this case, observation may be sufficient.
For Further Assistance Contact
Inspira Cancer Services:
Vineland: (856) 641-8670
SWOG S1304 CTSU
Woodbury: (856) 853-2075
A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or
Refractory Disease
Why the study is being done/Purpose:
RATIONALE/PURPOSE: This randomized phase II trial studies how well two doses of carfilzomib work with dexamethasone in treating patients with relapsed or
refractory multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in
chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
Giving carfilzomib together with dexamethasone may kill more cancer cells. This study is looking to see if giving a higher or lower dose of carfilzomib with
dexamethasone is more beneficial than the other.
Myeloma
PRINTED 6/18/2015
Page 12